Showing results (91-100 of 125) with videos related to
Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung CancerJoshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.Journal of Medicinal Chemistry|December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray CocrystallographyChristopher R Smith, Dan Chen, James G Christensen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.Nature Medicine|June 12, 2012
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemiaAlex Kentsis, Casie Reed, Kim L Rice, et al.The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.Pageof 13